HeartSciences PE Ratio 2022-2024 | HSCS
Current and historical p/e ratio for HeartSciences (HSCS) from 2022 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. HeartSciences PE ratio as of November 20, 2024 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| HeartSciences PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2024-11-19 | 2.64 | 0.00 | |
| 2024-07-31 | 3.85 | $-21.64 | 0.00 |
| 2024-04-30 | 0.09 | $-32.00 | 0.00 |
| 2024-01-31 | 0.15 | $-48.00 | 0.00 |
| 2023-10-31 | 0.25 | $-61.00 | 0.00 |
| 2023-07-31 | 0.87 | $-67.00 | 0.00 |
| 2023-04-30 | 0.89 | $-82.00 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.002B | $0.000B |
| Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical utility. Millions of ECGs are performed every week and the Company's objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences has one of the largest libraries of AI-ECG algorithms and is developing AI-ECG solutions to be made available on either a hardware agnostic cloud-based platform or its proprietary MyoVista? wavECG(TM) device, to help identify cardiovascular disease in any care setting worldwide in a manner to best suit different care providers. HeartSciences' first product candidate for FDA clearance, the MyoVista? wavECG(TM), or the MyoVista(R), is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tempus AI (TEM) | United States | $8.497B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $5.276B | 164.53 |
| Hims & Hers Health (HIMS) | United States | $5.141B | 130.72 |
| Privia Health (PRVA) | United States | $2.533B | 211.10 |
| Enovis (ENOV) | United States | $2.529B | 17.15 |
| IRhythm Technologies (IRTC) | United States | $2.362B | 0.00 |
| Azenta (AZTA) | United States | $2.001B | 99.78 |
| Omnicell (OMCL) | United States | $1.964B | 64.26 |
| Clover Health Investments (CLOV) | United States | $1.644B | 0.00 |
| 10x Genomics (TXG) | United States | $1.643B | 0.00 |
| Schrodinger (SDGR) | United States | $1.378B | 0.00 |
| Phreesia (PHR) | United States | $1.072B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.650B | 0.00 |
| Standard BioTools (LAB) | United States | $0.562B | 0.00 |
| Talkspace (TALK) | United States | $0.522B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.520B | 0.00 |
| Definitive Healthcare (DH) | United States | $0.483B | 83.60 |
| Health Catalyst (HCAT) | United States | $0.459B | 0.00 |
| TruBridge (TBRG) | United States | $0.244B | 71.22 |
| Pulmonx (LUNG) | United States | $0.237B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.214B | 0.00 |
| American Well (AMWL) | United States | $0.122B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.107B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.075B | 0.00 |
| HeartBeam (BEAT) | United States | $0.067B | 0.00 |
| 111 (YI) | China | $0.053B | 0.00 |
| CareCloud (CCLD) | United States | $0.046B | 0.00 |
| Zepp Health (ZEPP) | China | $0.040B | 0.00 |
| SHL Telemedicine (SHLT) | Israel | $0.040B | 0.00 |
| Outset Medical (OM) | United States | $0.039B | 0.00 |
| Movano (MOVE) | United States | $0.020B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.019B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.014B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.013B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.012B | 0.00 |
| MSP Recovery (LIFW) | United States | $0.010B | 0.00 |
| Precipio (PRPO) | United States | $0.009B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.006B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.006B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.004B | 0.00 |
| Syra Health (SYRA) | United States | $0.004B | 0.00 |
| Zhongchao (ZCMD) | China | $0.002B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.000B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.000B | 0.00 |